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1  | INTRODUC TION
Waiting lists for kidney transplantation worldwide are set to become 
longer as demands continue to outstrip supplies.1,2 In Spain, the 
number of waitlisted patients remains around 4000, which exceeds 
the annual number of kidney transplantations performed.2 Although 
there is room to expand the use of donation after brain death (DBD) 
kidneys, additional sources also need to be considered such as dona‐
tion after circulatory death (DCD).
In the early 1990s, interest in DCD donors emerged as a via‐
ble alternative to circumvent the shortage of organs. In 1995, the 
Maastricht classification system categorized DCD donors according 
 
Received:	1	July	2018  |  Revised:	29	November	2018  |  Accepted:	10	December	2018
DOI: 10.1111/ajt.15243
O R I G I N A L  A R T I C L E
Uncontrolled donation after circulatory death: A cohort 
study of data from a long‐standing deceased‐donor kidney 
transplantation program
Ana I. Sánchez‐Fructuoso1  | Isabel Pérez‐Flores1 | Francisco Del Río2 |  
Jesús Blázquez3 | Natividad Calvo1 | Maria Á. Moreno de la Higuera1 | Angel Gómez3 | 
Santiago Alonso‐Lera4 | Ana Soria2 | Manuel González2 | Ervigio Corral5 |  
Alonso Mateos6 | Jesús Moreno‐Sierra2 | Cristina Fernández Pérez7
Abbreviations: cDCD, controlled donation after circulatory death; CPR, cardiopulmonary 
resuscitation; DBD, donation after brain death; DCD, donation after circulatory death; 
DGF,	 delayed	 graft	 function;	 ECD,	 expanded‐criteria	 brain‐dead	 donors;	 PNF,	 primary	
nonfunction; SCD, standard‐criteria brain‐dead donors; uDCD, uncontrolled donation 
after circulatory death.
1Nephrology	Department,	Hospital	Clínico	






Carlos, Universidad Complutense, Madrid, 
Spain
4Surgery	Department,	Hospital	Clínico	San	
Carlos, Universidad Complutense, Madrid, 
Spain
5SAMUR, Madrid, Spain
6SUMMA112, School of Medicine, Francisco 
de Vitoria University, Madrid, Spain
7Preventive	Medicine,	Hospital	Clínico	San	
Carlos, Universidad Complutense, Madrid, 
Spain
Correspondence
Ana I. Sánchez Fructuoso
Email: sanchezfructuoso@gmail.com
Despite good long‐term outcomes of kidney transplants from controlled donation 
after circulatory death (DCD) donors, there are few uncontrolled DCD (uDCD) pro‐
grams.	 This	 longitudinal	 study	 compares	 outcomes	 for	 all	 uDCD	 (N	=	774)	 and	 all	
donation	after	brain	death	(DBD)	(N	=	613)	kidney	transplants	performed	from	1996	
to 2015 at our center. DBD transplants were divided into those from standard‐crite‐
ria	(SCD)	(N	=	366)	and	expanded‐criteria	(N	=	247)	brain‐dead	donors	(ECD).	One‐,	
5‐, and 10‐year graft survival rates were 91.7%, 85.7%, and 80.6% for SCD; 86.0%, 
75.8%, and 61.4% for ECD; and 85.1%, 78.1%, and 72.2% for uDCD, respectively. 
Graft survival was worse in recipients of uDCD kidneys than of SCD (P	=	.004)	but	
better than in transplants from ECD (P	=	.021).	The	main	cause	of	graft	 loss	 in	the	
uDCD transplants was primary nonfunction. Through logistic regression, donor 
death due to pulmonary embolism (OR 4.31, 95% CI 1.65‐11.23), extrahospital CPR 
time	≥75	minutes	(OR1.94,	95%CI	1.18‐3.22),	and	in‐hospital	CPR	time	≥50	minutes	
(OR 1.79, 95% CI 1.09‐2.93) emerged as predictive factors of primary nonunction. 
According to the outcomes of our long‐standing kidney transplantation program, 
uDCD could help expand the kidney donor pool.
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donation: donation after circulatory death (DCD), donors and donation: extended criteria, 
kidney transplantation/nephrology, organ procurement, organ procurement and allocation
1694  |     SÁNCHEZ‐FRUCTUOSO ET al.
to whether circulatory arrest was uncontrolled (categories I and II) 
or controlled (categories III and IV).3 This classification scheme was 
subsequently redefined.4,5
Today, most DCD donors are category III, such that the majority of 
studies addressing the use of DCD donors have focused on controlled 
donors (cDCD).6‐22 In contrast, there are scarce data available on out‐
comes such as long‐term renal function and graft survival in recipients of 
uncontrolled DCD (uDCD) kidneys.4,23‐27	France,	The	Netherlands,	and	
Spain have some experience with this category of donor, and our center 
has probably the world's longest standing experience with uDCD.4,27
The factors that affect outcome after transplantation using kid‐
neys from controlled DCD have been well‐established, whereas for 
uDCD donors these are largely unknown. In this article, we compare 
outcomes of uDCD and DBD transplants in our cohort of kidney 




In 1989 our hospital started a program to obtain organs from cDCD. 
In 1996, this program was extended to include organs procured from 
uDCD, ie, persons who die suddenly on the street of irreversible car‐
diac arrest. A formal agreement was established with the ambulance 
services of our city whereby, following unsuccessful cardiopulmonary 
resuscitation (CPR), patients are transferred to our hospital. This pro‐
tocol in no case affects any CPR maneuver. First, all measures and 
times specified in the established CPR procedures are undertaken, 
and only when cardiac arrest is considered irreversible (when an ef‐
fective heartbeat cannot be recovered after a stipulated period of usu‐
ally 30 minutes, or when the lesions provoking the cardiac arrest are 
incompatible with life) is the patient evaluated as a potential donor. 
When an individual has been classified as a candidate for donation, the 
emergency team continues with cardiac massage, mechanical ventila‐
tion, and intravenous fluid perfusion to maintain adequate hemody‐
namic conditions during transport to the hospital. Upon arrival, the 
transplant coordination team checks the conventional prerequisites 
for donation and then transfers the deceased donor to the operating 
room where the femoral vein and artery are cannulated via an inci‐
sion in the right side of the groin and connected to a cardiopulmonary 
bypass machine with external oxygenation. In 96.5% of uDCD donors, 
hypothermic regional perfusion was used and in the remaining 3.5% 
normothermic regional perfusion (when the liver was also procured). 
This procedure has been described in detail in a preliminary study.27 




From 2002, the age limit for donation was raised to 60 years, CPR time 
to 150 minutes and warm ischemia time to 180 minutes. Remaining 
criteria are the standard criteria established for DBD. After kidney 
extraction, a biopsy specimen of the graft is obtained for histological 
viability testing. The preservation solution used is Celsior® (Genzyme 
Polyclonals, Catalent Limoges S.A.S., France). If cold ischemia time 
(from the start of cold storage to the onset of graft perfusion) is longer 
than 24 hours the donor is rejected.
Since	November	2005,	provided	there	were	consumables	avail‐
able, uDCD grafts were maintained on a perfusion machine until the 
time of transplant (65.8% of cases).
Recipient characteristics were the same for receiving a kidney 
from a uDCD or a brain‐dead donor.
2.2 | Study population
The study design was a retrospective analysis of data from a pro‐
spective multipurpose cohort. The cohort was composed of all con‐
secutive kidney transplants performed at our hospital from January 
1996 to December 2015. Over this period, 1473 kidneys were re‐
covered from uDCD donors (Figure 1). Of these, 930 (63.1%) proved 
suitable for transplant: 804 were transplanted at our center and the 
remaining 126 were sent to other centers as we had no recipients 
with compatible blood groups. The remaining 543 (36.9%) grafts 
were rejected for transplant mainly because of poor perfusion, in‐
adequate renal histology findings, and severe arteriosclerosis in the 
donor. Remaining causes are detailed in Figure 1.
Over the study period, 1534 deceased‐donor transplants were con‐
ducted at our hospital: 807 were from DCD donors (789 from uDCD 
donors and 18 from cDCD donors) and 727 from DBD donors (Figure 2). 
Patients were excluded if they had undergone a dual kidney transplant 
(N	=	114	from	DBD	donors	and	15	from	uDCD	donors)	or	were	cDCD	
transplant	recipients	(N	=	18).	This	left	a	study	population	of	1387	adult	
kidney transplant recipients, 774 from uDCD donors and 613 from DBD 
donors.	The	DBD	recipients	were	divided	according	to	UNOS	criteria28 
into those receiving a kidney from a standard‐criteria brain‐dead donor 
(SCD)	(N	=	366)	or	from	an	expanded‐criteria	brain‐dead	donor	(ECD)	
(N	=	247).	Analysis	 included	follow‐up	data	collected	until	May	2018.	
Ten recipient patients were lost to follow‐up at a median time post‐
transplant of 5 years (minimum 2 years; maximum 12 years).
In Figure 3, we provide the total number of kidney transplants 
from deceased donors conducted at our hospital.
2.3 | Treatment and outcome measures
Over the study period, the immunosuppression treatment given to 
kidney transplant recipients varied. From January 1996 to July 1996, 
patients mainly received quadruple sequential therapy (antithy‐
mocyte globulin 7 days, azathioprine, prednisone from the time of 
transplant and cyclosporine from day 5). From this time onwards, the 
immunosuppression regimen was cyclosporine or tacrolimus plus 
prednisone and mycophenolate. From March 2001, anti‐IL2 recep‐
tor antibodies were added to the tacrolimus (starting dose 0.1 mg/
kg/day to achieve trough levels around 5 ng/mL) plus prednisone 
and mycophenolate regimen in DCD and ECD recipients. After 
August 2008, most uDCD recipients were treated with antithymo‐
cyte globulin 5‐7 days, mycophenolate, prednisone from the time of 
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transplant and tacrolimus introduced from day 5. This regimen was 
used in some DBD recipients. Subsequent ambulatory patient man‐
agement did not vary according to donor type.
Primary	nonfunction	 (PNF)	was	defined	as	a	never	 functioning	
graft following transplant. All nephrectomy specimens were exhaus‐
tively	reviewed	to	establish	the	cause	of	PNF.
Delayed graft function (DGF) was defined as a need for dialysis in 
the first week posttransplant. When managing patients with DGF, a 
graft biopsy is obtained every 7‐9 days to check for subclinical acute 
rejection.
Graft survival (noncensored for death) was calculated from the 
date of transplantation to the date of irreversible graft failure signi‐
fied by return to long‐term dialysis (or retransplantation) or the date 
of the last follow‐up during the period when the transplant was still 
functioning or to the date of death.
Graft survival censored for death was calculated from the date 
of transplantation to the date of irreversible graft failure signified 
by return to long‐term dialysis (or retransplantation) or the date of 
last follow‐up during the period when the transplant was still func‐
tioning. In the event of death with a functioning graft, the follow‐up 
period was censored at the date of death.
Estimated glomerular filtration rate was calculated using the ab‐
breviated Modification of Diet in Renal Disease equation.29
The study protocol received institutional review board approval 
according to Spanish legislation.
2.4 | Statistical analysis
Continuous variables, expressed as means and standard deviation 
(SD), were compared by analysis of variance. The chi‐square test or 
F I G U R E  1   Use of kidneys from 
uncontrolled donation after circulatory 
death (uDCD) donors at our center 
(Hospital	Clínico	San	Carlos,	Madrid,	
Spain) over the period January 1996 to 
December 2015 [Color figure can be 
viewed at wileyonlinelibrary.com]
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Fisher's test were used to compare categorical variables. Asymmetric 
variables, provided as the median and first and third quartiles (IQR: 
p25‐p75), were compared by the median test.
The annual transplantation rate was calculated as the number of 
patients transplanted in the year *100/(prevalent patients on January 1 
plus new patients added in the year). Odds ratios and their 95% con‐
fidence intervals (CI) were calculated as the relative effect of rates of 
a given variable for 2015 referred to corresponding rates for 1996.
Kaplan‐Meier curves were used to examine graft survival. 
Associated P values were derived from the log‐rank test.
F I G U R E  2  Deceased‐donor	kidney	transplants	performed	at	our	center	(Hospital	Clínico	San	Carlos,	Madrid,	Spain)	over	the	period	
January 1996 to December 2015. DCD, donation after circulatory death; uDCD, uncontrolled donation after circulatory death; cDCD, 
controlled donation after circulatory death; DBD, donation after brain death; SCD, standard‐criteria brain‐dead donors; ECD, expanded‐
criteria brain‐dead donors [Color figure can be viewed at wileyonlinelibrary.com]
F I G U R E  3  Total	number	of	kidney	transplants	performed	by	year	from	deceased	donors	at	our	center	(Hospital	Clínico	San	Carlos,	
Madrid,	Spain)	over	the	period	January	1996	to	December	2015.	White	bars	=	DBD	transplants,	gray	bars	=	DCD	transplants,	black	bars	=	
total transplants from deceased donors [Color figure can be viewed at wileyonlinelibrary.com]
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To identify donor factors possibly associated with graft loss due 
to	PNF,	we	conducted	a	univariate	analysis	including	the	variables:	
donor sex, age, and cause of death; warm and cold ischemia times; 
regional perfusion (hypothermic or normothermic); machine preser‐
vation; recipient sex, age, and cause of end‐stage renal disease; prior 
transplantation;	 preformed	 anti‐HLA	 antibodies;	 HLA	 mismatch;	
calcineurin inhibitor treatment pretransplant; and era. Cutoffs for 
cardiac arrest and CPR times were based on the 75th percentile of 
the sample. A logistic regression model was constructed adjusted by 
backward stepwise regression based on maximum likelihood estima‐
tors including variables showing a P < .15 in the univariate analysis. 
Odds ratios and their significance were calculated for each variable 
according to criteria for entry (P =	.05)	and	removal	(P = .10). Possible 
interactions were assessed by introducing multiplicative terms 
(cause of death*cardiac arrest time, cause of death*CPR time, cause 
of death*donor age, cause of death*cold ischemia time, perfusion 
machine* cardiac arrest time, perfusion machine* CPR time). The dis‐
criminative ability of the logistic models was determined through the 
area under the receiver operating characteristic curve (AUROC) and 
95% CI. Models were calibrated by comparing predicted versus ob‐
served probabilities after calculating these from the adjusted model 
coefficients; probabilities were divided into intervals on the basis of 
their	deciles.	The	Hosmer‐Lemeshow	test	was	used	to	assess	good‐
ness of fit. Model selection was based on that showing the highest 
discriminative power, good calibration, viable capacity, and fulfilling 
the principle of parsimony (explaining the maximum variability out‐
come variable with the smallest number of variables included). Data 
were available for all transplants.
All statistical tests were performed using the packages SPSS 
20.0 and STATA 12.0. Significance was set at P < .05.
3  | RESULTS
3.1 | Impacts on the waiting list
In Figure 4 we provide the numbers of prevalent patients on the kid‐
ney transplantation waiting list on January 1 of each year, as well 
F I G U R E  4  Numbers	of	prevalent	patients	on	the	waiting	list	on	January	1	(gray	bars),	incident	patients	(black	bars),	and	transplants	
(white bars) by year [Color figure can be viewed at wileyonlinelibrary.com]
F I G U R E  5   Median times to transplant from addition to 
our waiting list by year. Box plots represent the median and 
interquartile range. Outliers indicated with small dots
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as the number of incident patients on our list and transplants con‐
ducted each year. Because of the increased number of transplants 
performed at the program outset, individuals listed at other centers 
were transferred to our hospital, introducing wide variability in inci‐
dent patients.
Figure 5 shows the median time until transplantation from when 
the patient is waitlisted at our center.
The median time from dialysis onset to transplantation was 
27.8 months over the period 1990‐1995 (IQR 14.1‐54.7) and 
19.6 months for the era 1996‐2015 (IQR 8.9‐36.2) (P < .001). Annual 
deceased‐donor transplant rate increased from 29% in 1996 to 
42.3% in 2015 (OR 1.75; IQR 1.07‐2.87, P	=	.0241)	 and	 exceeded	
65% in some years such as 2002 and 2003. Over the study period, 
101 patients received a deceased‐donor transplant in a predialysis 
situation.
3.2 | Outcomes
Median follow‐up was 10.8 years (IQR 6.6‐15.3).
Table 1 lists the general characteristics of the uDCD and DBD 
transplants. As expected, the groups were not comparable in terms 
of donor age, sex, cause of death, or recipient immunosuppression. 
Uncontrolled DCD were predominantly male and the most common 
cause of death was heart disease. In uDCD recipients, cold ischemia 
time	was	shorter	at	the	expense	of	slightly	worse	HLA‐DR	compat‐
ibility. Uncontrolled donor time variables in minutes were cardiac 
arrest median 10 (IQR 5‐13), extrahospital CPR mean 62.8 (SD 20.6), 




Acute rejection was similar across the 3 groups. Kidney function 
was better in recipients of grafts from SCD at all follow‐up times. 
At 5 and 10 years, kidney function was better in uDCD than ECD 
recipients (P < .001 and P	=	.021,	 respectively).	 Graft	 survival	 in	
uDCD recipients was worse than in SCD recipients (P	=	.004)	but	
better than in ECD transplants (P	=	.021)	(Figure	6).	After	the	third	
month, graft survival times were practically parallel for trans‐
plants from uDCD donors and standard‐criteria donors. When 
grafts	lost	to	PNF	were	excluded	from	the	graft	survival	analysis,	
no differences were observed between uDCD and SCD recipients 
(P	=	.997).
As recipients of grafts from ECD were older than recipients of 
uDCD grafts, a subanalysis of graft survival in patients older than 
60 years was conducted. Mean recipient ages were comparable 
[65.8, 65.8, and 66.1 years for recipients of uDCD, SCD, and ECD, 
respectively (P	=	.369)].	 Graft	 survival	 (death	 censored)	 (Figure	7)	
was worse in recipients of ECD (P	=	.032	vs	uDCD	and	P	=	.042	vs	
SCD). Death not‐censored graft survival was better in recipients of 
uDCD compared to ECD (P	=	.047).
Figure 8 shows graft survival (death censored) after stratifying 
recipients according to the presence or absence of DGF. Patients 
with	PNF	were	excluded.	 In	patients	with	DGF,	graft	 survival	was	
better in uDCD vs SCD transplant recipients (P	=	.014)	and	similar	
when DGF was present (P	=	.585).	Kidney	transplantation	from	ECD	
showed worse graft survival regardless of DGF. In SCD and ECD 
graft recipients with DGF, graft survival was significantly lower than 
in those without DGF (P < .001 and P	=	.012,	respectively).	However,	
in uDCD recipients, the presence of DGF was not related to a worse 
prognosis (P	=	.324).
Table S1 provides our 1‐year death‐censored graft survival rates 
by	era	and	Table	S2	 lists	PNF	causes	 in	 recipients	of	uDCD	grafts	
also by era.
3.3 | Primary nonfunction
The	causes	of	PNF	are	 summarized	 in	Table	2.	The	most	 frequent	
cause was glomerular, arteriolar, and arterial thrombosis with fibri‐
noid necrosis in arteriole and arterial walls in both kidneys of the 
same donor (Figure 9). In these transplants, the presence of anti‐
body‐mediated rejection or cellular‐mediated rejection was ruled 
out according to revised Banff 2017 classification criteria.30 These 
kidney grafts showed poor perfusion after declamping and were 
explanted during the transplant surgery itself or within 24 hours of 
surgery.	Other	causes	of	PNF	were	renal	artery	or	vein	thrombosis,	
associated with surgical problems or secondary to perigraft fluid col‐
lection and torsion or kinking of the renal vessels; in none of these 
grafts was fibrinoid necrosis detected.
To	 identify	 factors	 associated	 with	 graft	 loss	 due	 to	 PNF,	 we	
compared through logistic regression uDCD transplant recipients 
with	PNF	(N	=	96)	and	without	PNF	(N	=	678)	(Table	3).
According to logistic regression, the donor factors emerging 
as	predictive	of	PNF	were	death	by	pulmonary	embolism,	extra‐
hospital	CPR	time	≥75	minutes,	in‐hospital	CPR	time	≥	50	minutes,	
and era. The area under the multivariate analysis curve was 0.68 
(95%CI	0.62‐0.74)	 and	 the	Hosmer‐Lemeshow	 test	P	=	.930.	The	
predicted and observed incidences of this model are depicted in 
Figure S1.
We also compared the data included in the multivariate analysis 
by different time intervals (Table S3). This comparison revealed sig‐
nificant differences mainly in uDCD characteristics. Comparing the 
era 2006‐2010 with 1996‐2000, donors and recipients were older, 
CPR and bypass times were longer, cold ischemia time was shorter, 
and a perfusion machine was used in a greater percentage of cases 
(Table 3).
Pretransplant graft biopsy findings revealed no data that could in‐
dicate compromised subsequent graft viability (data not shown). When 
pulmonary embolism and trauma were excluded from the analysis, the 
risk	of	PNF	decreased	from	OR	3.31	(95%	CI	1.89‐5.80)	to	2.22	(95%	CI	
1.15‐4.27) in uDCD recipients compared to SCD recipients.
4  | DISCUSSION
The use of uDCD has enabled our center to notably increase the 
number of kidney transplantations and thus also considerably 
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shorten the waiting list. This uDCD program has had an impor‐
tant effect in increasing the annual deceased‐donor transplant 
rate compared with previous eras; for example, it was 1.75 times 
higher in 2015 than in 1996 (42% vs 29%, respectively). Our 
experience could be of interest to other countries. For exam‐
ple, according to the Organ Procurement and Transplantation 
TA B L E  1   Donor and recipient characteristics in uDCD, standard‐criteria, and expanded‐criteria kidney transplants
uDCD (N = 774) SCD (N = 366) ECD (N = 247) P value
Donor age (y), mean (SD) 40.4 (10.9) 34.6 (12.2) 62.7 (7.7) <.001
Male donors, % 85.9 61.7 56.9 <.001
Cause of donor death, % <.001
Cerebrovascular stroke 1.7 40.2 81.8
Trauma 12.1 43.4 11.3
Cardiopathy 78.6 2.5 1.2
Anoxic encephalopathy 2.5 9.3 3.2
Pulmonary embolism 2.7 0.5 0
Other 2.5 4.1 2.4
Recipient age (y), mean (SD) 50.4 (13,3) 47.3 (13.1) 56.1 (12.3) <.001
Male recipients, % 65.0 62.6 63.6 .716
Time on dialysis (mo.), median (IQR) 15.2 (6.6‐30.4) 19.9 (7.9‐36.4) 20.0 (8.9‐39.4) .006
Body mass index (kg/m2), mean (SD) 26.0 (4.4) 25.6 (4.3) 25.9 (4.2) .463
Cold ischemia time, mean (SD) 17.4 (3.3) 19.5 (4.4) 20.3 (4.9) <.001
Diabetic recipients, % 11 7.1 18.2 <.001
HLA	mismatch,	mean	(SD)
DR 1.25 (0.66) 1.14 (0.69) 1.18 (0.66) .022
B 1.53 (0.58) 1.52 (0.59) 1.51 (0.53) .864
A 1.41 (0.63) 1.37 (0.54) 1.32 (0.65) .100
HLA‐DR	mismatch,	% .075
0 12.0 17.5 14.3
1 50.5 50.6 53.1
2 37.5 31.7 32.7
HLA	A	and	B	mismatch,	% .576
0 0 0 0
1‐2 28.9 31.1 32.0
3‐4 71.1 68.9 68.0
Regraft, % 14.6 17.5 16.2 .431
Preformed	anti‐HLA	antibodies,	% .099
0% 85.3 80.6 78.9
1%‐19% 8.0 9.6 8.9
20%‐49% 3.1 4.6 4.5
≥50% 3.6 5.2 7.7
Initial immunosuppression treatment, %
Polyclonal antibodies 41.7 18.0 29.1 <.001
Anti‐IL2 receptor antibodies 43.9 12.6 21.5 <.001
Cyclosporine 13.0 35.5 40.1 <.001
Tacrolimus 84.2 63.9 59.9 <.001
Azathioprine 3.4 14.5 13.8 <.001
Mycophenolate 96.6 84.4 83.0 <.001
mTOR inhibitors 3.5 1.9 5.7 .044
Other 0.5 0.3 0.4 .840
uDCD, uncontrolled donation after circulatory death; SCD, standard‐criteria brain‐dead donors; ECD, expanded‐criteria brain‐dead donors.
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TA B L E  2   Outcomes recorded in the uDCD, SCD, and ECD transplant recipients
uDCD (N = 774) SCD (N = 366) ECD (N = 247) P value
Primary	nonfunction,	N	(%) 96 (12.3) 15 (4.1) 20 (8.1) <.001
Acute rejection 6 (0.8) 6 (1.6) 5 (2.0)
Surgical complication 30 (3.9) 7 (1.9) 7 (2.8)
Transplant renal vein thrombosis 6 (0.8) 1 (0.3) 3 (1.2)
Transplant renal artery thrombosis 8 (1.0) 3 (0.8) 3 (1.2)
Hemorrhage 6 (0.7) 2 (0.5) 1 (0.4)
Arteriovenous fistula 2 (0.3) 0 (0) 0 (0)
Urological complications 5 (0.6) 1 (0.3) 0 (0)
Torsion of transplant vessels 2 (0.3) 0 (0) 0 (0)
Iliac artery thrombosis 1 (0.1) 0 (0) 0 (0)
TMA 51 (6.6) 0 (0) 3 (1.2)
Other 9 (1.2) 2 (0.5) 5 (2.0)
Need	for	dialysis	in	immediate	posttransplant	period,	N	(%)a 445 (65.1) 63 (17.7) 58 (25.1) <.001
Acute	rejection,	N	(%) 223 (30.1) 125 (34.2) 69 (27.9) .217
Biopsy‐proven 219 (28.2) 96 (26.2) 55 (22.3) .171
Clinically suspected 14 (1.8) 29 (7.9) 14 (5.7) <.001
Estimated filtration rate 1 year posttransplant, mL/min, 
mean (SD)
46.2 (15.7) 56.9(16.9) 44.8 (16.5) <.001
Estimated filtration rate 5 years posttransplant, mL/min, 
mean (SD)
46.0(16.2) 54.1 (16.5) 39.6 (14.6)b <.001
Estimated filtration rate 10 years posttransplant, mL/min, 
mean (SD)
48.6 (17.6) 57.6 (20.0) 40.0 (15.4)c <.001
Proteinuria 1 years posttransplant, mg (day, median (IQR) 223 (126‐457) 179 (104‐351) 243 (130‐513) .005
Proteinuria 5 years posttransplant, mg (day, median (IQR) 208 (128‐456) 172 (108‐328) 221 (133‐524) .063
Proteinuria 10 years posttransplant, mg (day, median (IQR) 234 (126‐434) 160 (101‐319) 230 (158‐456) <.001
Graft survival (death censored), % (SE) {number at risk} <.001d
1 year 85.1 (1.3) {639} 91.7 (1.4) {331} 86.0 (2.2) {199}
5 years 78.1 (1.5) {485} 85.7 (1.9) {282} 75.8 (2.9) {133}
10 years 72.2 (1.8) {277} 80.6 (2.2) {197} 61.4 (3.7) {68} 
Graft survival (death not censored), % (SE) {number at risk} <.001e
1 year 82.7 (1.4) {639} 90.4 (1.5) {331} 81.0 (2.5) {199}
5 years 71.1 (1.7) {485} 80.7 (2.1) {282} 64.4 (3.1) {133}
10 years 60.1 (2.0) {277} 68.2 (2.5) {197} 43.7 (3.6) {68}
Graft	survival	(death	censored)	excluding	grafts	lost	to	PNF,	
% (SE) {number at risk}
<.001f
1 year 97.2 (0.6) {639} 95.7 (1.1) {331} 93.6 (1.6) {199}
5 years 90.9 (1.2) {485} 89.9 (1.6) {282} 83.1 (2.7) {133}
10 years 84.6 (1.6) {277} 85.0 (2.0) {197} 67.9 (3.8) {68}
Causes	of	graft	loss,	N	(%) <.001
Acute rejection 29 (3.7) 20 (5.5) 11 (4.5)
IFTA 63 (8.1) 40 (10.9) 41 (16.6)
Surgical complications 33 (4.3) 9 (2.5) 7 (2.8)
Glomerular, arteriolar, and arterial thrombosis with 
fibrinoid necrosis
51 (6.6) 0 (0) 3 (1.2)
Other 32 (4.1) 18 (4.9) 23 (9.3)
Patient survival up to 10 years, % (SE) {number at risk} <.001
(Continues)
     |  1701SÁNCHEZ‐FRUCTUOSO ET al.
Network/Scientific	 Registry	 for	 Transplant	 Recipients	 (OPTN/
SRTR) 2015 Report, 47.8% of patients waiting for transplant 
would accept an ECD kidney.1 Considering our graft survival rates 
in the uDCD kidney recipients, accepting an uDCD kidney could 
be a feasible option to reduce a patient's waiting time.
Our data indicate worse graft survival and kidney function rates 
for	 uDCD	 transplants	 than	 for	 SCD	 transplants.	 However,	 these	
rates were at least comparable to those observed for ECD trans‐
plants. Graft survival in our ECD recipients may seem low compared 
to recent data, though we should underscore that this is a historic 
series dating back to 1996. In the past few years, 1‐year graft sur‐
vival (death censored) at our center in recipients of grafts from ECD 
has improved (Table S2). In a recent meta‐analysis 31 comparing ECD 
and SCD transplants, pooled graft survival probabilities (death not 
censored) were 59.2% and 75.1% at 5 years, respectively. Our results 
for both uDCD and ECD are improved over these reported figures: 
71.1% and 64.4%, respectively, and similar to the 5‐year survival 
for	ECD	transplants	of	about	64%	quoted	in	the	OPTN/SRTR	2013	
Annual Data Report.32
Our worse outcomes for uDCD compared SCD transplants can 
be	attributed	to	more	PNF.	Reported	kidney	graft	PNF	rates	in	uDCD	
transplant recipients in the larger patient series range from 1.8% 26 
to 20%.23,24	Our	PNF	rate	was	12%	and	5	and	10	year	graft	survival	
rates were 78% and 72%, ie, higher than published rates.23,24,26 If 
we compare our data with the DCD donor transplant results pro‐
vided	in	the	OPTN/SRTR	2016	Report	33 (mostly controlled DCD), 
our survival rates for uDCD transplants were initially lower though 
comparable at 5 years (75% vs 78.1%).
The main cause of graft lost in our cohort of uDCD recipients 
was	PNF.	Hence,	excluding	transplants	showing	PNF,	graft	survival	
rates were comparable (Table 2). It therefore seems that uDCD 
kidneys could be a valuable contribution to the donor pool if this 
high	PNF	rate	were	somehow	improved.	Research	efforts	assess‐
ing	this	type	of	donation	should	try	to	identify	risk	factors	for	PNF.	
PNF	 secondary	 to	 glomerular,	 arteriolar,	 and	 arterial	 thrombosis	
with fibrinoid necrosis was described from the start of uDCD pro‐
grams.34 We suggest ischemia reperfusion injury as a likely cause, 
as this lesion usually appears immediately after reperfusion and 
F I G U R E  6   Actuarial graft survival 
in renal transplants according to donor 
type. uDCD, uncontrolled donation 
after circulatory death (solid line); SCD, 
standard‐criteria brain‐dead donors 
(dotted line); and ECD, expanded‐criteria 
brain‐dead donors (broken line). The log‐
rank test was used to calculate P values. 
Data were obtained from our center over 
the period January 1996 to December 
2015. The log‐rank test was used to 
calculate P values. uDCD vs ECD P < .021; 
SCD vs uDCD P	=	.004
TA B L E  2   (Continued)
uDCD (N = 774) SCD (N = 366) ECD (N = 247) P value
1 year 96.2 (0.7) {639} 98.3 (0.7) {331} 92.8 (1.7) {199}
5 years 89.6 (1.2) {485} 93.9 (1.3) {282} 83.7 (2.6) {133}
10 years 82.2 (1.7) {277} 84.8 (2.1) {197} 69.7 (3.9) {68}
uDCD, uncontrolled donation after circulatory death; SCD, standard‐criteria brain‐dead donors; ECD, expanded‐criteria brain‐dead donors; IFTA, in‐
terstitial fibrosis and tubular atrophy; TMA, thrombotic microangiopathy; SE, standard error.
aRecipients with primary nonfunction excluded. 
bP < .001 versus uDCD. 
cP	=	.021	versus	uDCD.	
dP < .021 uDCD versus ECD; P	=	.004	SCD	versus	uDCD.	
eP	=	.001	SCD	versus	ECD;	P < .001 uDCD versus ECD. 
fP	=	.997	SCD	versus	uDCD;	P < .001 SCD versus ECD; P < .001 uDCD versus ECD. 
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in both grafts of a single donor. Moreover, we carefully reviewed 
medical records and histological findings in nephrectomy speci‐
mens to rule out the possibility of rejection or primary disease re‐
currence. It is known that the endothelium is a target of choice for 
injury by ischemia reperfusion.35 In experimental models of isch‐
emia reperfusion injury, renal perfusion in peritubular capillaries 
is compromised within minutes of unclamping.36 Endothelial dys‐
function/injury and apoptosis compromise microcirculatory renal 
blood flow through decreased vasodilatory capacity, coagulation 
activation and the formation of microvascular thrombi, and in‐
creased rolling/adhesion of inflammatory cells.37,38 Kwon et al39 
assessed intraoperative graft biopsies after reperfusion in 21 
F I G U R E  7   Actuarial graft survival 
(death	censored)	in	recipients	≥60	years.	
uDCD, uncontrolled donation after 
circulatory death (solid line); SCD, 
standard‐criteria brain‐dead donors 
(dotted line); and ECD, expanded‐criteria 
brain‐dead donors (broken line). The log‐
rank test was used to calculate P values. 
uDCD vs SCD P	=	.611;	uDCD	vs	ECD	
P	=	.032;	SCD	vs	ECD	P	=	.042
F I G U R E  8   Actuarial graft survival in renal transplants according to the presence or absence of delayed graft function. A, Actuarial graft 
survival in kidney transplants without delayed graft function. B, Actuarial graft survival in kidney transplants with delayed graft function. 
Comparison of graft survival in the absence of delayed graft function uDCD vs SCD P	=	.585;	uDCD	vs	ECD	P	=	.002;	SCD	vs	ECD	P < .001. 
Comparison of graft survival in the presence of delayed graft function uDCD vs SCD P	=	.014;	uDCD	vs	ECD	P < .001; SCD vs ECD P < .250. 
Comparison of graft survival in recipients with and without delayed graft function: uDCD P	=	.324,	SCD	P < .001, ECD P	=	.012.	uDCD,	
uncontrolled donation after circulatory death (solid line); SCD, standard‐criteria brain‐dead donors (dotted line); and EDCD, expanded‐
criteria brain‐dead donors (broken line). The log‐rank test was used to calculate P values
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deceased donor renal allografts using fluorescence microscopy to 
examine vascular smooth muscle and endothelial cell integrity as 
well as peritubular interstitial pericytes in the biopsies. The reper‐
fused, transplanted kidneys exhibited postischemic injury to the 
renal vasculature, as demonstrated by disorganization/disarray of 
the actin cytoskeleton in vascular smooth muscle cells and disap‐
pearance of von Willebrand factor from vascular endothelial cells. 
Damage to peritubular capillary endothelial cells was more severe 
in subjects who were to suffer acute renal failure than in those 
rapidly recovering their graft function. Endothelial integrity of per‐
itubular capillaries was better preserved, and pericytes were more 
pronounced in patients who would show recovery of their graft 
function compared with those showing delayed graft function. In 
addition, ischemia‐reperfusion injury can increase complement‐ 
associated injury through complement activation.40 Accordingly 
and considering that DCD organs sustain an inevitable period of 
warm ischemia after circulatory arrest (between cessation of car‐
diopulmonary function and onset of preservation), we hypoth‐
esize that following reperfusion, endothelial damage takes place 
with serious repercussions on graft function after transplantation. 
Warm ischemia time is much longer for uDCD than cDCD grafts. 
Although our inclusion criteria for donor candidates were rigor‐
ous (cardiac arrest and CPR times), we had no variable available 
to monitor the effectiveness of CPR. At present, we are testing 
the use of capnography for this purpose. In our study, as variables 
predictive	of	PNF,	we	identified	prolonged	warm	ischemia,	donor	
death secondary to pulmonary embolism, and era. In donors dying 
from pulmonary embolism, CPR maneuvers would likely be less ef‐
ficient at maintaining organs adequately oxygenated. A negative 
result	of	our	 study	 is	 the	higher	number	of	grafts	 lost	 to	PNF	 in	
the medium‐final stages than in the initial stages of our program. 
Thus, most of these losses occurred in the period 2006‐2010 with 
respect to 1996‐2000. By analyzing the data it emerges that these 
losses were associated with a slightly older donor age and suffer‐
ing longer warm ischemia times, likely explaining the worse out‐
comes. Accordingly, we believe the strict surveillance of protocols 
is essential both those implemented by the outside and in‐hospi‐
tal teams to ensure proper donor management and optimal organ 
protection	 and	 preservation.	 Hence,	 individuals	 whose	 cause	 of	
death is pulmonary embolism need to be meticulously assessed 
and efforts made to shorten warm ischemia time. In DCD kidney 
transplantation multivariate risk studies including data from a large 
national database, donor age was identified as an independent risk 
factor	 for	 PNF	 (reviewed	 in	 Ref.41). Donor age was not related 
here	to	an	 independent	 risk	of	PNF.	The	explanation	for	 this	dif‐
ference could be first that our donors were younger, and second 
that most studies have focused on cDCD. Recently, Peters‐Sengres 
et al23 compared using data from the Dutch Organ Transplantation 
Registry, 97 recipients of uDCD kidneys with 1441 recipients of 
cDCD kidneys. These authors observed a greater rate of nonvia‐
bility (19.6% vs 9.6%), higher incidence of DGF, and worse survival 
in the uDCD graft recipients. They also found that donor age and 
warm/cold	 ischemia	times	were	 linked	to	PNF	in	these	uDCD	re‐
cipients.	These	results	confirm	earlier	findings	by	Hoogland	et	al24
Brook et al42 found that in patients with DGF, graft survival was 
better for DCD than DBD kidneys. The reasons for the higher rate 
of graft survival in DBD recipients are not clear although the au‐
thors hypothesized they may be related to the absence in DCD of 
the complex events associated with brain death. The link between 
DGF and graft outcome in DCD kidney transplants is unclear and 
some studies have identified worse graft outcomes in recipients 
showing DFG20,21 whereas others have not.13	Here,	DGF	was	not	
found to confer a worse prognosis in recipients of uDCD kidneys, in 
line with our prior experience4,27 and with Spanish43 experience in 
general, whereas DGF did determine a worse prognosis in recipients 
of DBD grafts.
Of note, we should mention the large number of grafts from 
uDCD donors that were rejected (see Figure 1). Among the most 
frequent causes was the poor perfusion of the procured graft, 
which likely reflects inadequate CPR. The other two more com‐
mon causes were histologic findings (high Remuzzi score) and se‐
vere donor atheromatosis, which is not unexpected considering 
the	 leading	 cause	 of	 death	was	 heart	 disease.	Notwithstanding,	
our fast approach to donor candidates designed to cut down the 
duration of warm ischemia leaves little time for donor data col‐
lection. This determines that donors with infectious diseases or 
with a history of drug abuse or a kidney condition (polycystosis, 
multicystosis, pyelonephritis) and other disorders that encompass 
what we describe in Figure 2 as a poor macroscopic appearance 
of the graft could initially enter our fast‐track protocol. Current 
donation rates in our country are 25.7% for deceased donors and 
26.8% for DCD though we lack specific data for uDCD.44 Donor 
rejection	 rates	 provided	 in	 the	 OPTN/SRTR	 2016	 Report33 are 
>60%	of	kidneys	recovered	from	donors	≥65	years	and	>50%	for	
donors aged 50‐64 years, although rates of kidneys recovered 
from DCD donors and not transplanted are better than ours (ie, 
lower).	However,	most	of	these	were	from	cDCD.33
We are aware that some will have ethical concerns about 
uncontrolled donation and would like to highlight two points 
F I G U R E  9   Glomeruli with erythrocyte congestion, fibrin 
thrombi, and fibrinoid necrosis in the arteriole (Masson's trichrome, 
×200) [Color figure can be viewed at wileyonlinelibrary.com]
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TA B L E  3   Univariate and multivariate logistic regression for primary nonfunction in uncontrolled donation after circulatory death kidney 
transplants
Univariate (N = 774 transplants)
Multivariate (N = 774 
transplants)
Viable trans‐
plants (N = 678) PNF (N = 96)
Odds ratio (95% 
CI) P Odds ratio (95% CI) P
Cause	of	death,	N	(%) .002 .005
Trauma 80 (11.8) 14 (14.6) 1.38 (0.75‐2.56) .303 1.73 (0.89‐3.34) .103
Pulmonary embolism 13 (1.9) 8 (8.3) 4.84 (1.95‐12.13) .001 4.31 (1.65‐11.23) .003
Other 585 (86.3) 74 (77.1) 1 1
Donor age, mean (SD) 40.5 (11.0) 40.1 (10.2) 1.00 (0.98‐1.02) .767
Donor	sex	male,	N	(%) 587 (86.6) 78 (81.3) 0.67 (0.38‐1.17) .162
Cardiac	arrest	time,	N	(%) .449
<13 min 498 (73.5) 74 (77.1) 1
≥	13	min 180 (26.5) 22 (22.9) 0.82 (0.50‐1.36)
Extrahospital	CPR	time,	N	(%) .068 .010
<75 min 492 (72.6) 61 (63.5) 1 1
≥75	min 186 (27.4) 35 (36.5) 1.52 (0.97‐2.38) 1.94 (1.18‐3.22)
In‐hospital	CPR	time	≥	50	min,	N	(%) .024 .021
<50 min 480 (70.8) 57 (59.4) 1 1
≥50	min 198 (29.2) 39 (40.6) 1.66 (1.07‐2.59) 1.79 (1.09‐2.93)
Regional perfusion .836
Normothermic 24 (3.5) 3 (3.1) 1
Hypothermic 654 (96.5) 93 (96.9) 0.88 (0.26‐2.98)
Bypass	time,	N	(%) .058
<215 min 512 (75.5) 81 (84.4) 1
≥215	min 166 (24.5) 15 (15.6) 0.57 (0.32‐1.02)
Cold ischemia time min, mean (SD) 17.4 (3.3) 17.3 (3.4) 0.99 (0.93‐1.06) .763
Use	of	perfusion	machine,	N	(%) 248 (36.6) 35 (36.5) 1.00 (0.64‐1.55) .982
Recipient age, mean (SD) 50.7 (13.1) 49.3 (13.7) 0.99 (0.98‐1.01) .337
Recipient	sex	male,	N	(%) 438 (64.6) 65 (67.7) 1.15 (0.73‐1.81) .551
Cause	of	end‐stage	renal	disease,	N	(%) .797
Glomerulonephritis 221 (32.6) 25 (26.0) 1
Diabetes mellitus 72 (10.6) 9 (9.4) 1.11 (0.49‐2.48) .808
Adult polycystic kidney disease 99 (14.6) 14 (14.6) 1.25 (0.62‐2.51) .530
Chronic interstitial disease 104 (15.3) 20 (20.8) 1.70 (0.90‐3.20) .100
Nephroangiosclerosis 113 (16.7) 17 (17.7) 1.33 (0.69‐2.56) .395
Other 22 (3.2) 4 (4.2) 1.61 (0.51‐5.04) .416
Unknown 47 (6.9) 7 (7.3) 1.32 (0.54‐3.22) .547
Transplant	era,	N	(%) .002 .001
1996‐2000 107 (15.8) 5 (5.2) 1 1
2001‐2005 210 (31.0) 31 (32.3) 3.16 (1.19‐8.36) .020 2.56 (0.94‐6.96) .069
2006‐2010 191 (28.2) 43 (44.8) 4.82 (1.85‐12.53) .001 4.64 (1.75‐12.32) .002
2011‐2015 170 (25.1) 17 (17.7) 2.14 (0.77‐5.97) .146 1.82 (0.62‐5.36) .275
Previous	transplantation,	N	(%) .337
No 583 (86.0) 79 (82.3) 1
Yes 95 (14.0) 17 (17.7) 1.32 (0.75‐2.33)
(Continues)
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related to this issue. First, the determination of death always 
occurs in an in‐hospital setting and is conducted by a physician 
outside the donation team and team originally responsible for 
the advanced CPR. Lack of cardiocirculatory function is assessed 
during a 5‐minute period of observation. Immediately after this, 
cardiac compression and mechanical ventilation are resumed to 
ensure organ viability, and this is followed by regional abdominal 
perfusion with oxygenated blood.45 The second point is that the 
mean time between initial cardiac arrest and balloon placement 
in the aorta was 116 minutes in our study. Thus, there is no doubt 
as to the neurologic situation of the patient at this point and its 
irreversibility.45
The main limitation of this study is that it was based on real‐
world and not randomized data. In effect, some transplants were 
performed almost 30 years ago, during which time donor accep‐
tance criteria and immunosuppressive treatments have varied. 
Nevertheless,	we	considered	we	should	describe	the	whole	patient	
cohort in order to detect the factors that could lead to a worse 
prognosis in uDCD graft recipients. At our center it is common 
practice to allocate kidneys from aged donors to older recipients 
and we apply different immunosuppression regimens to the differ‐
ent transplant types as we feel that treatment should be tailored to 
suit the characteristics of both recipient and donor. These differ‐
ences will lead to biases capable of explaining some differences in 
results. This is why we separately examined graft survival in recipi‐
ents of 60 years or older and provide survival data for the different 
eras. Another limitation is that it was a single‐center study though 
with much experience with managing this type of transplant. We 
also lacked external validation. We should highlight that the cohort 
of patients examined was prospectively collected using a well‐ 
defined follow‐up protocol in which losses were few. Regardless of 
these limitations, the main goal of our study was to show that uDCD 
donors could be an adequate source of kidneys for transplant and to 
identify risk factors in the uDCD donors for nonviability.
According to the outcomes of our long‐standing deceased‐donor 
kidney transplantation program, donation after uncontrolled circula‐
tory death could be a viable option to expand the kidney donor pool. 
This is important because transplantation has both financial and life 
year advantages over dialysis in that it adds about 5 quality‐adjusted 
years of life compared with dialysis.46 We should stress that not only 
the transplantation team but also the emergency services have the 
opportunity to play a key role in creating an effective uDCD program 
and thus help shorten the waiting list.
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Univariate (N = 774 transplants)
Multivariate (N = 774 
transplants)
Viable trans‐
plants (N = 678) PNF (N = 96)
Odds ratio (95% 
CI) P Odds ratio (95% CI) P
Preformed	anti‐HLA	antibodies,	N	(%) .660
0% 583 (86.0) 79 (82.3) 1
1%‐19% 50 (7.4) 10 (10.4) 1.48 (0.72‐3.03) .280
20%‐49% 20 (2.9) 4 (4.2) 1.48 (0.49‐4.43) .487
≥50% 25 (3.7) 3 (3.1) 0.89 (0.26‐3.00) .845
HLA	A	and	B	mismatch,	N	(%) .504
0 0 0
1‐2 199 (29.4) 25 (26.0) 1
3‐4 479 (70.6) 71 (74.0) 1.18 (0.73‐1.92)
HLA‐DR	mismatch,	N	(%) .350
0 79 (11.7) 14 (14.6) 1
1 349 (51.5) 42 (43.8) 0.68 (0.35‐1.30) .245
2 250 (36.9) 40 (41.7) 0.90 (0.47‐1.75) .761
Use of calcineurin inhibitor pretrans‐
plantation,	N	(%)
.231
No 281 (41.4) 46 (47.9) 1
Yes 397 (58.6) 50 (52.1) 0.77 (0.50‐1.18)
Cutoff	 cardiac	 arrest	 and	CPR	 times	were	 based	 on	 the	 75th	 percentile	 of	 the	 sample.	Area	 under	 the	multivariate	 analysis	 curve	=	0.68	 (95%CI	
0.62‐0.74).	Hosmer‐Lemeshow	test	P	=	.516.
PNF,	primary	nonfunction;	CPR,	cardiopulmonary	resuscitation.
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